The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation
Open accessAbstract
Background—: Cerebral cavernous malformation (CCM) is a hemorrhagic stroke disease affecting up to 0.5% of North Americans that has no approved nonsurgical treatment. A subset of patients have a hereditary form of the disease due primarily to loss-of-function mutations in KRIT1, CCM2 , or PDCD10. We sought to identify known drugs that could be repurposed to treat CCM. Methods and Results—: We developed an unbiased screening platform based on both cellular and animal models of loss of function of CCM2 . Our discovery strategy consisted of 4 steps: an automated immunofluorescence and machine-learning–based primary screen of structural phenotypes in human endothelial cells deficient in CCM2, a secondary screen of functional changes in endothelial stability in these same cells, a rapid in vivo tertiary screen of dermal microvascular leak in mice lacking endothelial Ccm2 , and finally a quaternary screen of CCM lesion burden in these same mice. We screened 2100 known drugs and bioactive compounds and identified 2 candidates, cholecalciferol (vitamin D 3 ) and tempol (a scavenger of superoxide), for further study. Each drug decreased lesion burden in a mouse model of CCM vascular disease by ≈50%. Conclusions—: By identifying known drugs as potential therapeutics for CCM, we have decreased the time, cost, and risk of bringing treatments to patients. Each drug also prompts additional exploration of biomarkers of CCM disease. We further suggest that the structure-function screening platform presented here may be adapted and scaled to facilitate drug discovery for diverse loss-of-function genetic vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
EndMT contributes to the onset and progression of cerebral cavernous malformations
Maddaluno, L., Rudini, N., Cuttano, R., Bravi, L., Giampietro, C., Corada, M., Ferrarini, L., Orsenigo, F., Papa, E., Boulday, G., et al. (2013) · Nature · doi:10.1038/nature12207 · Cited by 486 · cited 1×
“Recent evidence suggests that endothelial-to-mesenchymal transition plays a critical role in the pathophysiology of CCM disease.(66) Through inhibition of transforming growth factor-β, a key driver of endothelial-to-mesenchymal transition, reduction in severity of disease in a mouse model of CCM disease was identified.”
BackgroundSelf-citation
Cited by
CellProfiler 3.0: Next-generation image processing for biology
McQuin, C., Goodman, A., Chernyshev, V., Kamentsky, L., Cimini, B. A., Karhohs, K. W., Doan, M., Ding, L., Rafelski, S. M., Thirstrup, D., et al. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2005970 · Cited by 1,825
Bray, M.-A., Singh, S., Han, H., Davis, C. T., Borgeson, B., Hartland, C., Kost-Alimova, M., Gustafsdottir, S. M., Gibson, C. C., & Carpenter, A. E. (2016) · Nature Protocols · doi:10.1038/nprot.2016.105 · Cited by 1,090
Self-citationThe molecular basis of endothelial cell plasticity
Dejana, E., Hirschi, K. K., & Simons, M. (2017) · Nature Communications · doi:10.1038/ncomms14361 · Cited by 441
Image-based profiling for drug discovery: due for a machine-learning upgrade?
Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D., & Carpenter, A. E. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00117-w · Cited by 389
Cerebral cavernous malformations arise from endothelial gain of MEKK3–KLF2/4 signalling
Zhou, Z., Tang, A. T., Wong, W.-Y., Bamezai, S., Goddard, L. M., Shenkar, R., Zhou, S., Yang, J., Wright, A. C., Foley, M., et al. (2016) · Nature · doi:10.1038/nature17178 · Cited by 332
Self-citationPlatinum nanozymes recover cellular ROS homeostasis in an oxidative stress-mediated disease model
Moglianetti, M., De Luca, E., Pedone, D., Marotta, R., Catelani, T., Sartori, B., Amenitsch, H., Retta, S. F., & Pompa, P. P. (2016) · Nanoscale · doi:10.1039/c5nr08358c · Cited by 264
Self-citationComplex Tissue and Disease Modeling using hiPSCs
Passier, R., Orlova, V., & Mummery, C. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.02.011 · Cited by 142
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
“…cells deficient in cerebral cavernous malformations 2 protein (CCM2; encoded by CCM2 , one of at least three genes associated with these malformations), active compounds were then triaged by functional studies in the same in vitro model and subsequently in inducible Ccm2 - knockout mice 68 .”
BackgroundPhuong, T. T. T., Redmon, S. N., Yarishkin, O., Winter, J. M., Li, D. Y., & Križaj, D. (2017) · The Journal of Physiology · doi:10.1113/jp275052 · Cited by 91
Self-citationEvolution and impact of high content imaging.
Way, G. P., Sailem, H., Shave, S., Kasprowicz, R., & Carragher, N. O. (2023) · SLAS Discovery · doi:10.1016/j.slasd.2023.08.009 · Cited by 67
Metadata
- Authors
- Gibson, C. C., Zhu, W., Davis, C. T., Bowman-Kirigin, J. A., Chan, A. C., Ling, J., Walker, A. E., Goitre, L., Delle Monache, S., Retta, S. F., Shiu, Y.-T. E., Grossmann, A. H., Thomas, K. R., Donato, A. J., Lesniewski, L. A., Whitehead, K. J., & Li, D. Y.
- Venue
- Circulation
- Published
- 2015-01-20
- Volume
- 131
- Issue
- 3
- Pages
- 289-299
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1985356361
- Cited by
- 175
- References
- 2
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.